Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma by Weisel, Katja et al.
1 
 
Health-Related Quality-of-Life Results from the Phase 3 OPTIMISMM Study: 
Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-
Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma  
 
Running head: HRQoL of PVd in Patients With RRMM 
 
Katja Weisel,1 Meletios Dimopoulos,2 Philippe Moreau,3 Munci Yagci,4 Alessandra Larocca,5 
Abraham S. Kanate,6 Filiz Vural,7 Nicola Cascavilla,8 Supratik Basu,9 Peter Johnson,10 Peter 
Byeff,11 Marek Hus,12 Paula Rodríguez-Otero,13 Ercan Muelduer,14 Pekka Anttila,15 Patrick J. 
Hayden,16 Maria-Theresa Krauth,17 Paulo Lucio,18 Dina Ben-Yehuda,19 Larisa Mendeleeva,20 
Shien Guo,21 Xin Yu,22 Lara Grote,22 Tsvetan Biyukov,23 Sujith Dhanasiri,23 Paul Richardson24 
 
1University Medical Center of Hamburg-Eppendorf, Hamburg, Germany and University Hospital 
of Tuebingen, Tuebingen, Germany; 2National and Kapodistrian University of Athens, Athens, 
Greece; 3University Hospital Hôtel-Dieu, Nantes, France; 4Gazi Universitesi Tip Fakultesi 
Hastanesi, Besevler, Turkey; 5Myeloma Unit, Division of Hematology, University of Torino, 
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy; 
6Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, West Virginia, 
United States; 7Ege University Hospital, Izmir, Turkey; 8Fondazione IRCSS Casa Sollievo Della 
Sofferenza, San Giovanni Rotundo, Italy; 9New Cross Hospital, Wolverhampton, University Of 
Wolverhampton, United Kingdom; 10Department of Haematology, Western General Hospital, 
Edinburgh, United Kingdom; 11Cancer Center of Central Connecticut, Southington, CT, United 
States; 12Samodzielny Publiczny Szpital Nr 1 W Lublinie, Lublin, Poland; 13University of 
Navarra, Pamplona, Spain; 14Medizinische Universitaet Wien, Vienna, Austria; 15Division of 
Hematology, Helsinki University and Helsinki University Hospital Comprehensive Cancer 
Center, Helsinki, Finland; 16St James Hospital-Cancer Clinical Trials Office, Dublin, Ireland; 
17Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical 
University of Vienna, Vienna, Austria; 18Champalimaud Center for the Unknown, Lisbon, 
Portugal; 19Hadassah Hospital, Jerusalem, Israel; 20National Research Center for Hematology of 
the Ministry of Healthcare of the Russian Federation, Moscow, Russia; 21Evidera, Waltham, 
MA, United States; 22Celgene Corporation, Summit, NJ, United States; 23Celgene International 
2 
 
Sàrl, Boudry, Switzerland; 24Jerome Lipper Multiple Myeloma Center, Department of Medical 
Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States. 
 
Corresponding author information: 
Name: Katja Weisel 
Institution/Address: University Medical Center of Hamburg-Eppendorf, Hamburg, Germany 
Email: k.weisel@uke.de 
Phone: +49 40 7410 51410 
 
Abstract 
In the randomized phase 3 OPTIMISMM study, the addition of pomalidomide to bortezomib and 
low-dose dexamethasone (PVd) resulted in significant improvement in progression-free survival 
(PFS) in lenalidomide-pretreated patients with relapsed or refractory multiple myeloma 
(RRMM), including lenalidomide refractory patients. Here we report health-related quality of 
life (HRQoL) results from this trial. Patients received PVd or Vd in 21-day cycles until disease 
progression or discontinuation. HRQoL was assessed using the EORTC QLQ-C30, QLQ-MY20, 
and EQ-5D-3L instruments on day 1 of each treatment cycle. Mean score changes for global 
QoL, physical functioning, fatigue, side effects of treatment domains, and EQ-5D-3L index, 
were generally stable over time across treatment arms. Proportion of patients who experienced 
clinically meaningful worsening in global QoL and other domains of interest were similar. These 
HRQoL results with PVd along with previously demonstrated improvement in PFS vs Vd 
continue to support its use in patients with RRMM. 
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Research Availability of Data and Materials 
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healthcare practitioners, and independent researchers in order to both improve scientific and 
medical knowledge as well as to foster innovative treatment approaches. Researchers interested 




The global incidence of multiple myeloma (MM) increased by an estimated 126% between 1990 
and 2016 [1]. In 2016, MM was responsible for nearly 100,000 deaths worldwide with an age-
adjusted standardized death rate of 1.5 per 100,000 persons. MM is characterized by 
hyperproliferation of malignant plasma cells in the bone marrow and immune dysfunction [2,3] 
The natural course of MM is one of relapse and remittance [4,5]. With each subsequent relapse, 
patient prognosis and quality of life (QoL) worsen [6-8]. Moreover, the burden of illness in MM 
is high. Complications include hypercalcemia, renal impairment, anemia, and lytic bone lesions, 
which affect approximately 13%, 20% to 40%, 70%, and 80% of patients with MM, respectively 
[9].  
 
Given the burden of disease, it is not surprising that patients with MM have a lower health-
related QoL (HRQoL) compared with normative populations [10]. In assessing HRQoL up to 10 
years after diagnosis of MM, Mols et al. found that the European Organisation for Research and 
Treatment of Cancer (EORTC) QLQ-C30 subscales for QoL, dyspnea, and physical, role, and 
social functioning were most affected, irrespective of time since diagnosis [10]. Gulbrandsen et 
al. also found that patients with MM have worse HRQoL than the general population [11], with 
more pain and fatigue, reduced physical and role functioning, and worse overall QoL. Although 
QoL scores appeared to improve with treatment, patients continued to experience reduced 
physical and role functioning after 3 years of therapy.  
 
Management of relapsed or refractory MM (RRMM) necessitates multiple lines of therapy 
[4,12]. Evidence shows that with each additional line of therapy, disease resistance increases, 
resulting in reduced treatment response, immune system impairment, and worsened HRQoL 
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[4,6,13-15]. As with most cancer treatments, anti-myeloma treatment regimens aim to achieve 
maximum response and enhance survival while improving or maintaining HRQoL and 
minimizing treatment-related toxicity and patient discomfort [16,17]. 
 
Lenalidomide is a standard of care in patients with newly diagnosed MM who are transplant-
eligible [18,19] or transplant-ineligible [20–22]. In the post–autologous stem cell transplant 
settings, lenalidomide monotherapy is the only approved treatment [22–26]. Moreover, 
continuous therapy with lenalidomide until disease progression is now standard practice based on 
improved survival outcomes demonstrated in randomized phase 3 clinical trials [20,21]. As a 
result, most patients in current clinical practice will become refractory to lenalidomide in early 
lines of treatment [27]. Until OPTIMISMM, phase 3 clinical data regarding subsequent treatment 
regimens in this patient population were lacking [24,28,29]. 
 
OPTIMISMM was the first phase 3 trial to prospectively evaluate a triplet regiment in early 
RRMM (median of 2 prior lines of therapy) and to demonstrate improved efficacy in patients 
who were all lenalidomide pretreated and a majority of whom were lenalidomide refractory 
(70%). In this trial, PVd significantly reduced the risk of disease progression or death by 39% 
(median PFS 11.2 vs 7.1 months [hazard ratio 0.61, 95% CI 0.49-0.77, P < .0001]) and led to a 
significantly higher overall response rate (82.2% vs 50.0%) compared with Vd [30]. The safety 
of PVd was consistent with the known profile of each component.  
 
The objective of this analysis was to evaluate the effect of PVd versus Vd on HRQoL in patients 
with RRMM who had previously been treated with lenalidomide. Specifically, this analysis 
sought to address whether adding pomalidomide to Vd would maintain the same HRQoL as that 
achieved with Vd alone. 
 
Methods 
Study Design and Data Source 
The OPTIMISMM study was a phase 3, multicenter, randomized, open-label, active-controlled 
trial that compared PVd with Vd in patients with RRMM. Details of the study design and 
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primary results, have been previously described [30]. Key enrolment and treatment information 
is outlined below. 
 
The study enrolled adult patients with RRMM who had received 1 to 3 prior anti-myeloma 
regimens and had previously been treated with a lenalidomide-containing regimen. Patients were 
randomly assigned to receive PVd (n = 281) or Vd (n = 278) in 21-day treatment cycles until 
disease progression or treatment discontinuation. In cycles 1 to 8, bortezomib (1.3 mg/m2) was 
administered intravenously or subcutaneously on days 1, 4, 8, and 11, and oral dexamethasone 
(20 mg/day for patients aged ≤ 75 years, 10 mg/day for patients > 75 years) was administered on 
days 1, 2, 4, 5, 8, 9, 11, and 12. From cycles 9 on, bortezomib was administered on days 1 and 8, 
and oral dexamethasone was administered on days 1, 2, 8, and 9. Patients in the PVd group 
additionally received oral pomalidomide (4 mg/day) on days 1 to 14 of each 21-day cycle. 
 
Outcomes of Interest 
HRQoL was assessed using the EORTC QLQ-C30 and MM module (QLQ-MY20) and the 
EQ-5D-3L instrument on day 1 of each 21-day cycle (before treatment administration) and at the 
end-of-treatment visit.  
 
The QLQ-C30 and QLQ-MY20 scales range from 1 to 100. For QLQ-C30, a higher score for the 
global QoL or functional domains indicates better functioning or health status. For QLQ-MY20, 
a higher score for disease symptoms and side effects of treatment indicates worsening symptoms 
or adverse events. 
 
The primary domain of interest was the global health status/QoL domain of the QLQ-C30. 
Secondary domains of interest included the physical functioning, pain, and fatigue domains of 
the QLQ-C30; disease symptoms and side effects of treatment domains of the QLQ-MY20; and 
health utility index of the EQ-5D-3L. Exploratory domains of interest included the remaining 
QLQ-C30 and QLQ-MY20 domains. Results from the exploratory analyses are provided in 




For the QLQ-C30 and QLQ-MY20, an improvement of ≥ 10 points was used to define a 
responder [31]. To facilitate interpretation of the results, mean QLQ-C30 scores from an 
international study of 15,386 individuals from the general population were used as a reference 
[32]. A deterioration of ≥ 0.10 points from baseline was used as the cutoff value for the EQ-5D-
3L health utility index [33]. 
 
Statistical Analysis 
Data from the OPTIMISMM study obtained up to October 26, 2017 were used for the present 
HRQoL analyses. All statistical analyses were performed using SAS version 9.4 or higher. A 
detailed HRQoL analysis plan was signed on January 25, 2018, before the study database lock. 
 
Adherence rates for completion of the HRQoL assessments were assessed at each visit. For 
QLQ-C30 and QLQ-MY20, adherence was defined as completion of ≥ 50% of the items. For the 
EQ-5D-3L, adherence was defined as completion of the 5 dimensions. A 2-sided Fisher exact 
test was used to compare the proportion of adherent patients at each visit between treatment 
groups. 
 
The intent-to-treat (ITT) population comprised all patients randomized in the study. The primary 
analyses of HRQoL data were based on the HRQoL-evaluable population: all randomized 
patients who completed the QLQ-C30 at baseline and ≥ 1 post-baseline assessment. Descriptive 
statistics for baseline scores for each HRQoL domain, key demographics, and disease 
characteristics were summarized for each treatment group based on the HRQoL-evaluable 
population. Changes in HRQoL scores from baseline at each post-baseline visit were also 
summarized descriptively for each treatment (cross-sectional analysis). A 2-sample t test was 
used to compare treatment groups. 
 
As a post hoc analysis of the HRQoL-evaluable population, area under the curve (AUC) for 
change from baseline was calculated for each QLQ-C30 and QLQ-MY20 domain using the 
trapezoidal rule, with adjustment for time between baseline and each patient’s last visit. 
Descriptive statistics were calculated. There was no imputation for missing intermittent 
assessments when calculating the AUC. Differences in AUCs between treatment groups were 
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assessed by analysis of covariance with adjustment for randomization strata. The least-square 
(LS) mean treatment group difference (PVd − Vd) and corresponding 95% CI were calculated. 
Hedges g effect size and corresponding 95% CI were also calculated. 
 
A mixed-model repeated measure (MMRM) analysis was used to estimate the treatment effects 
over time for each QLQ-C30 and QLQ-MY20 domain (longitudinal analysis) and the EQ-5D-3L 
health utility index and to assess the differences in treatment effects between groups. Within-
group and between-group differences were assessed at each visit by calculating the LS mean 
change from baseline and 95% CI. 
 
Instrument scoring and missing items were handled in accordance with the developer’s 
instructions [34,35]. Missing domain scores for a given assessment visit were not imputed in the 
primary HRQoL analyses. However, post hoc analyses were conducted to investigate missing 
data/dropout patterns and examine whether imputation of missing data using pattern-mixture 
models altered the findings of the primary analyses. 
 
For each QLQ-C30 and QLQ-MY20 domain and the EQ-5D-3L health utility index, the 
proportion of HRQoL-evaluable patients with a clinically meaningful change was calculated 
based on change from baseline score at day 1 of cycles 5, 9, 19, and 25. Cumulative distribution 
function curves for patients experiencing different degrees of change in global QoL at day 1 of 
cycles 5, 9, 19, and 25 were generated for each treatment group. The proportions of patients 
experiencing a clinically meaningful change were compared between treatment groups using the 
Cochran-Mantel-Haenszel test with modified ridit scores [36]. Adjusted odds ratios and 95% CIs 
were calculated. For each Cochran-Mantel-Haenszel analysis, the Breslow-Day test was used to 




The ITT population consisted of 559 patients: 281 (50.3%) in the PVd group and 278 (49.7%) in 
the Vd group (Figure 1). Of these patients, 15% did not have a QLQ-C30 assessment at the 
baseline visit (cycle 1 day 1), and 14% had no assessments at subsequent visits. Overall, 
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approximately 20% of the ITT population was excluded from the primary HRQoL analyses, as 
they did not meet the inclusion criteria for the HRQoL, resulting in an evaluable population of 
240 patients (85.4%) from the PVd group and 209 patients (75.2%) from the Vd group. 
 
Baseline demographics and clinical characteristics for the HRQoL-evaluable population are 
provided in Table 1. Most patients were ≤ 75 years old (84.2%) and had an ECOG PS of 0-1 
(96.0%); 69.9% of patients were refractory to lenalidomide, and 76.2% of patients had received 1 
or 2 prior anti-myeloma regimens. Baseline characteristics were similar for both treatment 
groups. Key differences in baseline characteristics between the HRQoL-evaluable and -
nonevaluable populations are listed in the Supplemental Results. 
 
Adherence rates are provided in Figure S1. When the number of eligible patients at each given 
visit was used as the denominator, adherence rates in the PVd group were high (≥ 80%) at all 
assessment visits except the end-of-treatment visit (Figure S1A). Adherence rates in the Vd 
group were high (≥ 80%) until cycle 20. Adherence rates were generally lower in the Vd group 
than in the PVd group and were significantly lower (P < .05) at cycles 1, 2, and 27. Only 
approximately half of patients in both groups completed the QLQ-C30 at the end-of-treatment 
visit. 
 
HRQoL at Baseline 
HRQoL scores at baseline are presented in Table 2. Mean (SD) baseline scores for the global 
QoL domain of the QLQ-C30 were similar in the 2 treatment groups: 61.0 (23.2) for the PVd 
group and 63.5 (21.3) for the Vd group.  
 
Compared with an age- and gender-matched general reference population, patients in this study 
had worse HRQoL scores across most domains (Table 2), indicating that HRQoL was impaired 
at baseline [32]. Generally, patients in the PVd group had worse mean baseline scores for the 
QLQ-C30 and QLQ-MY20 domains and EQ-5D-3L than the Vd group. However, the differences 





Treatment Effects on HRQoL 
Global Health Status, Function Domains, and Symptom Domains 
Mean changes in the QLQ-C30 global QoL domain were similar between treatment groups 
across all scheduled visits (Figure 2A). In the PVd group, the global QoL score showed a slight 
decrease during the first few cycles of treatment. 
 
Mean changes from baseline for the secondary domains of interest are provided in Figure 2 (B-
G). The physical functioning, fatigue, and side effects of treatment domains exhibited similar 
trends in changes in scores from baseline, with small, non–clinically meaningful worsening 
during the first few cycles of treatment. For these domains, no significant differences between 
treatment groups were observed at any assessment visit. For the QLQ-MY20 disease symptoms 
domain, scores in both treatment groups showed trends of improvement over time; no 
statistically significant differences between treatment groups were observed. The EQ-5D-3L 
health utility index score was also maintained for the duration of the treatment period for both 
groups. 
 
MMRM analyses showed statistically significant worsening in the LS mean QLQ-C30 global 
QoL domain score in patients in the PVd group compared with the Vd group at cycle 5 
(difference = −2.883; P = .0219) and cycle 9 (difference = −2.914; P = .0272) (Figure 3A). 
However, these differences were not clinically meaningful. After imputing missing data using a 
pattern-mixture model, the differences between treatment groups in LS mean changes from 
baseline were reduced and were not statistically significant at any assessment visit (Figure 3B).  
 
For the secondary domains of interest, results from the MMRM analysis were similar to those 
observed from the cross-sectional analysis (Figure 3C). There were no significant or clinically 
meaningful differences in the LS mean changes from baseline between treatment groups 
(Figure 3C). For most secondary domains of interest, the differences between treatment groups 





For the emotional functioning domain of the QLQ-C30, the adjusted LS mean AUC (95% CI) 
was −2.4 (−4.07 to −0.75) with PVd and 0.2 (−1.73 to 2.15) with Vd (P = .039) (Table 3). The 
effect size (Hedges g) was −0.20 (95% CI, −0.39 to −0.01), suggesting a “small” effect size. 
None of the other QLQ-C30 or QLQ-MY20 domains showed a treatment difference that was 
statistically significant or clinically meaningful. 
 
Clinically Meaningful Change  
The proportion of patients who experienced clinically meaningful worsening of the global QoL 
score was similar for both treatment groups: 23.9% to 33.0% with PVd and 28.8% to 50.0% with 
Vd (P > .05 for all cycles) (Table 4). The cumulative distribution function plots (Appendix 
Figure 2) show that use of different cutoffs for the definition of clinically meaningful worsening 
did not alter the results. 
 
For the secondary domains of interest, the proportion of patients who experienced clinically 
meaningful worsening showed no significant differences between treatment groups across all 
assessment visits (Table 4). The proportion of patients experiencing clinically meaningful 




Impaired HRQoL profoundly affects patients with RRMM. Considering changes to treatment 
regimens with the addition of novel agents and a move toward continuous therapy [39,40], this 
analysis assessed whether the addition of pomalidomide to the Vd combination would maintain 
the same HRQoL as that achieved with Vd alone in patients with RRMM treated previously with 
lenalidomide, including those refractory to lenalidomide after first- or early-line treatment. 
Overall, the results indicate that the addition of pomalidomide to Vd did not decrease HRQoL in 
this patient population. HRQoL was maintained over time in both the Vd and PVd treatment 




Consistent with previous reports from other clinical trials, HRQoL in patients from the 
OPTIMISMM study was lower at baseline compared with the general population 
[11,12,32,40,41]. This is expected since patients with RRMM experience symptoms each time 
their disease progresses [15]. Thus, patients are likely to have diminished HRQoL before 
treatment for relapsed or refractory disease begins [42]. 
 
No difference in clinically meaningful worsening of symptoms between treatment groups was 
observed during the study. However, non–clinically meaningful worsening in scores for the 
global QoL, physical functioning, role functioning, social functioning, fatigue, and side effects of 
treatment domains was observed during the first few cycles of treatment. This observation may 
be related to the safety profiles of the treatment regimens. Twice-weekly bortezomib dosing 
during the first 8 treatment cycles may have also attributed to these results. Similar trends were 
reported in both the VISTA and TOURMALINE-MM1 studies [40, 43]. However, VISTA was 
not designed to assess HRQoL differences between patients who received bortezomib once 
versus twice weekly and in TOURMALINE-MM1, an initial slight HRQoL worsening consistent 
with the toxicity profile of the investigational drugs was observed. Although an initial decline in 
HRQoL may have resulted from the incremental toxicity of adding pomalidomide to Vd, the 
subsequent improvement in HRQoL is likely the result of improved PFS with the PVd regimen.  
Furthermore, the observed differences became smaller when missing data were imputed in a post 
hoc analysis, suggesting that the difference between treatment groups in the primary analysis 
may have been overestimated. Typically, between-group improvements are not observed when 
comparing triple-therapy regimens with double-therapy combinations [40,41]. The results 
presented in this study indicate that the addition of pomalidomide to Vd did not adversely affect 
HRQoL.  
 
It is important that treatment regimens delay relapse or progression and prolong survival while 
maintaining or improving HRQoL [16,17]. However, no proven treatment strategy exists to 
manage RRMM in patients who have previously received lenalidomide and have experienced 
relapse [27]. Although the availability of several agents with unique modes of action has given 
clinicians multiple options for managing RRMM, selecting the right class or combination of 
agents to achieve optimal efficacy is complex and challenging. Moreover, selecting the best 
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treatment regimen for specific subgroups of patients with RRMM (eg, those with high-risk 
cytogenetics) is made more challenging by the lack of clarity in current treatment approaches [5].  
 
Pomalidomide has demonstrated improved efficacy when combined with Vd, and the results 
from this analysis show that the addition of pomalidomide to the Vd combination maintains the 
HRQoL of patients with RRMM, including those who were refractory to lenalidomide in early 
lines of therapy. Notably, while maintaining HRQoL, PVd increased PFS in the OPTIMISMM 
study [30]. This is important because MM disease progression is associated with deterioration of 
HRQoL. An appropriate treatment for RRMM should achieve improved disease control while 
maintaining HRQoL. 
 
The present study has certain limitations that may affect interpretation of the results. 
OPTIMISMM was an open-label study which may have influenced the HRQoL scores. In 
addition, approximately 15% of patients in the PVd group and 25% of patients in the Vd group 
were excluded from the HRQoL-evaluable population due to missing data. Excluded patients 
were sicker and had poor treatment outcomes, indicating that the primary analysis population for 
HRQoL (the HRQoL-evaluable population) may not have been representative of the overall 
OPTIMISMM study population (Table S1). The exclusions likely biased the results against the 
PVd treatment group, because patients excluded from the Vd group had worse treatment 
outcomes than patients excluded from the PVd group. To address these concerns, a post hoc 
sensitivity analysis was performed using pattern-mixture models to impute missing HRQoL data. 
Observed differences in HRQoL between treatment groups became smaller as a result of this 
imputation. Finally, across all assessment time points, fewer patients in the Vd treatment group 
than the PVd group were considered in the analyses based on the HRQoL-evaluable population. 
This could have been due to disease progression, and these patients were likely to be sicker and 
with a suboptimal response to treatment. The slight worsening of the global QoL score in the 
PVd group during the first few cycles of treatment may have been confounded by this. 
 
In summary, these data add valuable insight regarding HRQoL with PVd and complement the 
previously reported results on the efficacy and safety of this regimen [30]. It is important to 
consider that any potential survival benefits should be weighed against the overall burden of 
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treatment with respect to HRQoL. The results presented here indicate that addition of 
pomalidomide to Vd maintained HRQoL across all subgroups of patients with RRMM, 
suggesting that a longer progression-free interval can be achieved without compromising 
HRQoL. These results may be worth considering when making MM treatment decisions, as they 
may allow for individualization of the patient experience and help patients maintain HRQoL 
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Table 1. Baseline Demographics and Clinical Characteristics of HRQoL-Evaluable Patients 
Characteristic PVd 
(n = 240) 
Vd 
(n = 209) 
Overall 
(n = 449) 
Age, years, n (%) 
≤ 75 202 (84.2) 176 (84.2) 378 (84.2) 
> 75 38 (15.8) 33 (15.8) 71 (15.8) 
Sex, n (%) 
Male 135 (56.3) 108 (51.7) 243 (54.1) 
Female 105 (43.8) 101 (48.3) 206 (45.9) 
Region, n (%) 
US 33 (13.8) 35 (16.8) 68 (15.1) 
Non-US 207 (86.3) 174 (83.3) 381 (84.9) 
Prior anti-myeloma regimens, n (%) 
1 86 (35.8) 71 (34.0) 157 (35.0) 
2 104 (43.3) 81 (38.8) 185 (41.2) 
3 50 (20.8) 57 (27.3) 107 (23.8) 
ECOG PS, n (%) 
0 139 (57.9) 114 (54.6) 253 (56.4) 
1 94 (39.2) 84 (40.2) 178 (39.6) 
2 7 (2.9) 11 (5.3) 18 (4.0) 
β2M at screening, mg/L, n (%) 
< 3.5  133 (55.4) 116 (55.5) 249 (55.5) 
≥ 3.5 to ≤ 
5.5  69 (28.8) 60 (28.7) 129 (28.7) 
> 5.5 38 (15.8) 33 (15.8) 71 (15.8) 
ISS stage, n (%) 
I 128 (53.3) 109 (52.2) 237 (52.8) 
II 74 (30.8) 67 (32.1) 141 (31.4) 




(n = 240) 
Vd 
(n = 209) 
Overall 
(n = 449) 
Refractory to lenalidomide, n (%) 
Yes 172 (71.7) 142 (67.9) 314 (69.9) 
No 68 (28.3) 67 (32.1) 135 (30.1) 
Prior exposure to bortezomib, n (%) 
Yes 169 (70.4) 153 (73.2) 322 (71.7) 
No 71 (29.6) 56 (26.8) 127 (28.3) 
Baseline cytogenetic risk assessment, n (%) 
High 51 (21.3) 36 (17.2) 87 (19.4) 
Not high 119 (49.6) 105 (50.2) 224 (49.9) 
Missing 70 (29.2) 68 (32.5) 138 (30.7) 
Prior bone marrow or stem cell transplant, n (%) 
Yes 133 (55.4) 122 (58.4) 255 (56.8) 
No 107 (44.6) 87 (41.6) 194 (43.2) 
β2M, β2-microglobulin; ECOG PS, Eastern Cooperative Oncology Group performance status; HRQoL, 
health-related quality of life; ISS, International Staging System; PVd, pomalidomide, bortezomib, and 




Table 2. Mean HRQoL Scores at Baseline (HRQoL-evaluable population) 
Domain 






(n = 240) 
Vd 
(n = 209) 
Overall 
(n = 449) 
Reference 
(N = 15,386) 
QLQ-C30 
Global QoL 61.0 (23.2) 63.5 (21.3) 62.2 (22.4) 66.4 
Physical functioning 73.9 (23.7) 76.7 (22.0) 75.2 (22.9) 83.0 
Role functioning 74.4 (27.9) 77.0 (27.5) 75.6 (27.7) 83.7 
Cognitive 
functioning 
84.0 (21.1) 87.2 (17.5) 85.5 (19.5) 86.9 
Emotional 
functioning 
82.8 (20.5) 82.8 (19.0) 82.8 (19.8) 79.7 
Social functioning 79.4 (25.0) 83.4 (21.5) 81.3 (23.5) 88.5 
Fatigue 33.2 (26.1) 29.1 (22.8) 31.3 (24.7) 25.9 
Nausea and 
vomiting 
5.6 (15.8) 4.1 (12.7) 4.9 (14.4) 3.1 
Pain 28.3 (28.9) 26.8 (25.6) 27.6 (27.4) 24.0 
Dyspnea 19.4 (25.9) 17.4 (23.8) 18.5 (25.0) 16.8 
Insomnia 23.1 (27.7) 22.3 (27.6) 22.7 (27.6) 25.5 
Appetite loss 13.5 (25.0) 13.1 (24.4) 13.3 (24.7) 7.3 
Constipation 12.9 (25.1) 9.7 (20.0) 11.4 (22.9) 10.9 
Diarrhea 12.1 (22.8) 10.7 (20.4) 11.4 (21.7) 6.8 
Financial difficulties 13.4 (24.2) 10.4 (22.0) 12.0 (23.2) 8.4 
QLQ-MY20 
Disease symptoms 23.5 (22.1) 21.3 (19.2) 22.5 (20.8) NR 
Side effects 16.0 (15.3) 12.9 (13.1) 14.5 (14.4) NR 
Future perspective 66.8 (24.3) 65.6 (27.3) 66.2 (25.7) NR 
Body image 85.3 (25.3) 86.5 (25.4) 85.8 (25.4) NR 
EQ-5D-3L 
Health utility index 0.71 (0.30) 0.73 (0.28) 0.72 (0.29) NR 
NR, not reported; PVd, pomalidomide, bortezomib, and low-dose dexamethasone; QLQ-MY20, Quality-
of-Life Questionnaire for Patients With Multiple Myeloma; QoL, quality of life; Vd, bortezomib and low-
dose dexamethasone. 




Table 3. Area Under the Curve for Change From Baseline for the QLQ-C30 and QLQ-MY20 
Domains 
 PVd (n = 240) 
Vd 
(n = 209) PVd vs Vd 






(95% CI)b P value 
QLQ-C30      
Global QoL −2.0 
(−4.04 to 0.04) 
−1.1 
(−3.32 to 1.13) 
−0.92 
(−3.93 to 2.09) 
−0.06 





(−4.81 to −1.45) 
−1.9 
(−3.64 to −0.07) 
−1.32 
(−3.77 to 1.14) 
−0.10 





(−7.08 to −2.38) 
−3.8 
(−6.45 to −1.16) 
−1.05 
(−4.54 to 2.45) 
−0.06 





(−4.62 to −1.04) 
-1.8 
(−3.54 to -0.11) 
−0.95 
(−3.44 to 1.54) 
−0.07 





(−4.07 to −0.75) 
0.2 
(−1.73 to 2.15) 
−2.67 
(−5.20 to −0.14) 
−0.20 





(−5.69 to −1.25) 
−3.4 
(−5.71 to −1.01) 
−0.11 
(−3.35 to 3.14) 
−0.01 
(−0.19 to 0.18) 
.949 
Fatigue 4.1 (1.94-6.25) 4.1 (1.74-6.47) 0.05 
(−3.13 to 3.24) 
0.00 





(−2.61 to 0.82) 
0.1 
(−1.51 to 1.70) 
−0.99 
(−3.37 to 1.39) 
−0.08 
(−0.27 to 0.11) 
.415 
Pain −1.0 
(−3.50 to 1.43) 
−1.5 
(−4.15 to 1.15) 
0.46 
(−3.16 to 4.09) 
0.02 
(−0.16 to 0.21) 
.801 
Dyspnea 3.8 (1.34-6.34) 2.9 (0.86-4.91) 1.00 
(−2.29 to 4.28) 
0.06 
(−0.13 to 0.24) 
.551 
Insomnia −0.5 
(−3.31 to 2.23) 
1.7 
(−1.24 to 4.70) 
−2.28 
(−6.34 to 1.78) 
−0.11 
(−0.29 to 0.08) 
.270 
Appetite loss 0.6 
(−1.99 to 3.28) 
−0.6 
(−3.11 to 1.98) 
1.29 
(−2.37 to 4.95) 
0.07 
(−0.12 to 0.25) 
.488 
Constipation 5.5 (2.76-8.17) 3.4 (1.12-5.68) 2.04 
(−1.57 to 5.65) 
0.11 
(−0.08 to 0.29) 
.267 
Diarrhea 0.1 
(−2.63 to 2.83) 
−0.5 
(−2.68 to 1.59) 
0.68 
(−2.88 to 4.24) 
0.04 





(−0.42 to 3.81) 
−1.0 
(−3.10 to 1.02) 
2.73 
(−0.25 to 5.72) 
0.17 
(−0.01 to 0.36) 
.073 




(−6.12 to −2.49) 
−3.8 
(−5.59 to −2.05) 
−0.45 
(−3.01 to 2.12) 
−0.03 
(−0.22 to 0.16) 
.733 
Side effects 4.0 (2.63-5.40) 3.3 (1.87-4.68) 0.72 
(−1.27 to 2.71) 
0.07 




4.6 (2.45-6.83) 7.0 (4.37-9.66) −2.47 
(−5.84 to 0.90) 
−0.14 
(−0.33 to 0.05)  
.150 
Body image −3.5 
(−5.94 to −1.06) 
−2.9 
(−5.76 to 0.03) 
−0.53 
(−4.26 to 3.21) 
−0.03 




PVd, pomalidomide, bortezomib, and low-dose dexamethasone; QLQ-MY20, Quality of Life 
Questionnaire for Patients with Multiple Myeloma; QoL, quality of life; Vd, bortezomib and low-dose 
dexamethasone. 
a Least-square mean difference, adjusted for age (≤ 75 vs > 75 years), number of prior anti-myeloma 
regimens (1 vs > 1), and β2-microglobulin at screening (< 3.5 vs ≥ 3.5 mg/L to ≤ 5.5 vs > 5.5 mg/L). 
b Hedges g. 





Table 4. Proportions of Patients Experiencing Clinically Meaningful Worsening by Treatment 
Group and Visit  
Domain Visit 
PVd Vd 




 C5D1 200 33.0 146 28.8 1.18 0.73-1.89 .504 
 C9D1 158 31.0 86 31.4 0.99 0.55-1.79 .982 
 C19D1 67 23.9 24 29.2 0.90 0.30-2.70 .848 
 C25D1 36 25.0 8 50.0 0.21 0.03-1.57 .109 
Physical functioning 
 C5D1 200 37.5 146 32.9 1.23 0.78-1.95 .366 
 C9D1 158 31.6 86 39.5 0.73 0.42-1.27 .265 
 C19D1 67 29.9 24 29.2 1.00 0.34-2.90 .993 
 C25D1 36 22.2 8 25.0 0.23a 0.03-1.97 .091 
Fatigue 
 C5D1 200 51.5 146 44.5 1.36 0.88-2.12 .169 
 C9D1 158 44.3 86 44.2 0.96 0.56-1.65 .889 
 C19D1 67 41.8 24 41.7 1.22 0.44-3.41 .713 
 C25D1 36 33.3 8 37.5 0.79 0.11-5.58 .813 
Pain 
 C5D1 200 29.0 146 28.1 1.03 0.64-1.67 .889 
 C9D1 158 25.9 86 26.7 0.98 0.53-1.81 .948 
 C19D1 67 25.4 24 16.7 1.91 0.52-7.05 .34 
 C25D1 36 25.0 8 50.0 0.31 0.05-1.97 .169 
Disease symptoms 
 C5D1 199 15.6 144 16.0 0.95 0.52-1.73 .865 
 C9D1 159 17.0 84 17.9 0.95 0.46-1.96 .897 
 C19D1 67 20.9 23 13.0 2.25 0.51-9.97 .271 
 C25D1 36 13.9 8 25.0 0.68 0.06-7.62 .746 
Side effects of treatment 
 C5D1 199 37.2 144 33.3 1.13 0.72-1.78 .595 
 C9D1 159 33.3 84 34.5 0.89 0.5-1.57 .692 
 C19D1 67 28.4 23 34.8 0.53 0.18-1.58 .257 
 C25D1 36 25.0 8 25.0 0.47 0.07-3.24 .401 
EQ-5D-3L health utility index 
 C5D1 200 32.5 146 31.5 1.1 0.69-1.74 .694 
 C9D1 159 30.2 85 30.6 1.01 0.55-1.84 .979 
 C19D1 67 25.4 24 33.3 0.8 0.26-2.43 .705 
 C25D1 36 27.8 8 37.5 0.32 0.04-2.29 .261 
C, cycle; D, day; OR, odds ratio; PVd, pomalidomide, bortezomib, and low-dose dexamethasone; Vd, 
bortezomib and low-dose dexamethasone. 
A ≥ 10-point worsening from baseline was considered clinically meaningful for the QLQ-C30 and QLQ-
MY20; a ≥ 0.10-point worsening from baseline was considered clinically meaningful for the EQ-5D-3L. 
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OR was estimated using the Cochran-Mantel-Haenszel test with modified ridit scores stratified by 
randomization stratification factors.  
a A common OR at the C25D1 visit was reported, but the Breslow-Day test shows significant 
























Figure 1. Patient disposition in the HRQoL analysis based on the OPTIMISMM study. 
HRQoL, health-related quality of life; ITT, intent to treat; PVd, pomalidomide, bortezomib, and low-dose dexamethasone; Vd, 
bortezomib and low-dose dexamethasone. 
 
Figure 2. Observed change from baseline in HRQoL. A. Global QoL. B. Physical functioning. C. Fatigue. D. Pain. E. Disease 
symptoms. F. Side effects of treatment. G. EQ-5D-3L health utility index. For global QoL, physical functioning, and EQ-5D-3L health 
utility index, a negative value indicates worsening from baseline; for the other domains, a negative value indicates improvement from 
baseline. 
PVd, pomalidomide, bortezomib, and low-dose dexamethasone; SE, standard error; Vd, bortezomib and low-dose dexamethasone. 
* Difference in mean change between treatments significant at P < .05 (2-sample t test). Results are displayed up to the last cycle with 
n ≥ 10 in both treatment arms. 
 
Figure 3. Change from baseline in HRQoL: longitudinal analyses. A. Global QoL. B. Global QoL with missing data imputed. C. 
Secondary domains of interest. B. Secondary domains of interest with missing data imputed. LS mean changes and CIs were estimated 
based on a random intercept/slope model under the assumption of unstructured covariance and with the following covariates as fixed 
31 
 
effects: baseline domain score, age, number of prior anti-myeloma regimens, β2-microglobulin, treatment, visit, treatment-by-visit 
interaction, and baseline domain score-by-visit interaction.  








Key Baseline Differences Between Health-Related Quality of Life–Evaluable and –
Nonevaluable Populations 
Compared with the health-related quality of life (HRQoL)–evaluable population, the HRQoL-
nonevaluable population was, on average, older (20.0% vs 15.8% were older than 75 years), had 
more severe disease based on Eastern Cooperative Oncology Group performance status (13.6% 
vs 4.0% of patients had an Eastern Cooperative Oncology Group performance status of 2) and 
International Staging System stage (23.64% vs 15.81% of patients had stage III disease), and was 
more likely to live in the United States (49.1% vs 15.1%) (Table S1). The HRQoL-nonevaluable 
population also had worse overall survival, progression-free survival, and best overall response 
rate (44.6% of patients had a complete or partial response compared with 71.5% of the HRQoL-
evaluable population; data not shown). 
 
Treatment Effects on HRQoL: Exploratory Domains of Interest 
The remaining functional and symptom domains of the European Organisation for Research and 
Treatment of Cancer (EORTC) QLQ-C30 and QLQ-MY20 were evaluated as an exploratory 
analysis. HRQoL domain scores were maintained over time in both treatment groups, with the 
exception of the role functioning, social functioning, dyspnea, and constipation domains, which 
showed evidence of worsening during the first few cycles of treatment (data not shown). Scores 
for the future perspectives domain of the QLQ-MY20 improved over time in both treatment 
groups (data not shown).  
 
Overall, the pomalidomide, bortezomib, and low-dose dexamethasone (PVd) group exhibited 
worse least-squares (LS) mean changes from baseline than the bortezomib and low-dose 
dexamethasone (Vd) group. However, based on an MMRM analysis of all exploratory functional 
domains, the differences in LS mean changes from baseline between treatment groups were 
neither significant nor clinically meaningful (Figure S3A). No clinically meaningful between-
group differences in LS mean changes from baseline were observed for symptom domains 
(Figure S3B), despite statistically significant (P < .05) worsening of constipation and financial 
difficulties in the PVd group. Patients in the PVd group also experienced transient, clinically 




Across all domains, the proportions of patients who experienced clinically meaningful worsening 
were similar between treatment groups for all the assessment visits (Table S2). Exceptions were 
the financial difficulties domain at cycle 19, for which 7.5% and 16.7% of patients in the PVd 
and Vd groups, respectively, experienced clinically meaningful worsening (P = .050), and the 
body image domain, also at cycle 19, for which 20.9% and 39.1% of patients in the PVd and Vd 
groups, respectively, experienced clinically meaningful worsening (P = .031).  
 
Time to the first clinically meaningful worsening for the HRQoL-evaluable population was 
calculated as the time between randomization and the first time a patient’s change in a given 
domain was, at a minimum, 10 points worse than at baseline. In Cox proportional hazard 
regression analyses, time to first clinically meaningful worsening for all exploratory domains 





Table S1. Baseline Demographics and Clinical Characteristics Comparing Evaluable and Nonevaluable Patients 
 PVd Vd Overall 
HRQoL 
Evaluable 
(n = 240) 
HRQoL 
Nonevaluable 
(n = 41) 
HRQoL 
Evaluable 
(n = 209) 
HRQoL 
Nonevaluable 
(n = 69) 
HRQoL 
Evaluable 
(n = 449) 
HRQoL 
Nonevaluable 
(n = 110) 
Age, years, n (%) 
≤ 75 202 (84.2) 33 (80.5) 176 (84.2) 55 (79.7) 378 (84.2) 88 (80.0) 
> 75 38 (15.8) 8 (19.5) 33 (15.8) 14 (20.3) 71 (15.8) 22 (20.0) 
Sex, n (%) 
Male 135 (56.3) 20 (48.8) 108 (51.7) 39 (56.5) 243 (54.1) 59 (53.6) 
Female 105 (43.8) 21 (51.2) 101 (48.3) 30 (43.5) 206 (45.9) 51 (46.4) 
Region, n (%) 
US 33 (13.8) 20 (48.8) 35 (16.8) 34 (49.3) 68 (15.1) 54 (49.1) 
Non-US 207 (86.3) 21 (51.2) 174 (83.3) 35 (50.7) 381 (84.9) 56 (50.9) 
Prior anti-myeloma regimens, n (%) 
Missing 0 (0.0) 1 (2.4) 0 (0.0) 1 (1.5) 0 (0.0) 2 (1.8) 
1 86 (35.8) 12 (29.3) 71 (34.0) 24 (34.8) 157 (35.0) 36 (32.7) 
2 104 (43.3) 14 (34.2) 81 (38.8) 26 (37.7) 185 (41.2) 40 (36.4) 
3 50 (20.8) 14 (34.2) 57 (27.3) 18 (26.1) 107 (23.8) 32 (29.1) 
ECOG PS, n (%) 
0 139 (57.9) 10 (24.4) 114 (54.6) 23 (33.3) 253 (56.4) 33 (30.0) 
1 94 (39.2) 27 (65.9) 84 (40.2) 35 (50.7) 178 (39.6) 62 (56.4) 
2 7 (2.9) 4 (9.8) 11 (5.3) 11 (15.9) 18 (4.0) 15 (13.6) 
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 PVd Vd Overall 
HRQoL 
Evaluable 
(n = 240) 
HRQoL 
Nonevaluable 
(n = 41) 
HRQoL 
Evaluable 
(n = 209) 
HRQoL 
Nonevaluable 
(n = 69) 
HRQoL 
Evaluable 
(n = 449) 
HRQoL 
Nonevaluable 
(n = 110) 
β2M at screening, mg/L, n (%) 
< 3.5 133 (55.4) 23 (56.1) 116 (55.5) 31 (44.9) 249 (55.5) 54 (49.1) 
≥ 3.5 to ≤ 5.5  69 (28.8) 9 (22.0) 60 (28.7) 21 (30.4) 129 (28.7) 30 (27.3) 
> 5.5 38 (15.8) 9 (22.0) 33 (15.8) 17 (24.6) 71 (15.8) 26 (23.6) 
ISS stage, n (%) 
I 128 (53.3) 21 (51.2) 109 (52.2) 29 (42.0) 237 (52.8) 50 (45.5) 
II 74 (30.8) 11 (26.8) 67 (32.1) 23 (33.3) 141 (31.4) 34 (30.9) 
III 38 (15.8) 9 (22.0) 33 (15.8) 17 (24.6) 71 (15.8) 26 (23.6) 
Refractory to lenalidomide, n (%) 
Yes 172 (71.7) 28 (68.3) 142 (67.9) 49 (71.0) 314 (69.9) 77 (70.0) 
No 68 (28.3) 13 (31.7) 67 (32.1) 20 (29.0) 135 (30.1) 33 (30.0) 
Prior exposure to bortezomib, n (%) 
Yes 169 (70.4) 32 (78.1) 153 (73.2) 50 (72.5) 322 (71.7) 82 (74.6) 
No 71 (29.6) 9 (22.0) 56 (26.8) 19 (27.5) 127 (28.3) 28 (25.5) 
Baseline cytogenetic risk assessment, n (%) 
High 51 (21.3) 10 (24.4) 36 (17.2) 13 (18.8) 87 (19.4) 23 (20.9) 
Not high 119 (49.6) 18 (43.9) 105 (50.2) 27 (39.1) 224 (49.9) 45 (40.9) 
Missing 70 (29.2) 13 (31.7) 68 (32.5) 29 (42.0) 138 (30.7) 42 (38.2) 
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 PVd Vd Overall 
HRQoL 
Evaluable 
(n = 240) 
HRQoL 
Nonevaluable 
(n = 41) 
HRQoL 
Evaluable 
(n = 209) 
HRQoL 
Nonevaluable 
(n = 69) 
HRQoL 
Evaluable 
(n = 449) 
HRQoL 
Nonevaluable 
(n = 110) 
Prior bone marrow or stem cell transplant, n (%) 
Yes 133 (55.4) 28 (68.3) 122 (58.4) 41 (59.4) 255 (56.8) 69 (62.7) 
No 107 (44.6) 13 (31.7) 87 (41.6) 28 (40.6) 194 (43.2) 41 (37.3) 
β2M, β2-microglobulin; ECOG PS, Eastern Cooperative Oncology Group performance status; HRQoL, health-related quality of life; ISS, 







Table S2. Proportions of Patients Experiencing Clinically Meaningful Worsening by Treatment 
Group and Visit (exploratory domains of interest) 
Domain Visit 
PVd Vd 




 C5D1 200 36.5 146 37.0 0.99a 0.64-1.55 .979 
 C9D1 158 33.5 86 39.5 0.74 0.42-1.30 .300 
 C19D1 67 28.4 24 33.3 0.99 0.35-2.77 .979 
 C25D1 36 27.8 8 25.0 0.56 0.07-4.69 .586 
Emotional functioning 
 C5D1 200 25.0 146 17.1 1.59 0.93-2.71 .089 
 C9D1 158 26.6 86 19.8 1.41 0.73-2.71 .305 
 C19D1 67 20.9 24 20.8 1.14 0.35-3.75 .830 
 C25D1 36 2.8 8 12.5 0.20 0.01-4.17 .276 
Cognitive functioning 
 C5D1 200 28.0 146 26.7 1.07 0.66-1.74 .788 
 C9D1 158 29.1 86 33.7 0.81 0.46-1.43 .461 
 C19D1 67 32.8 24 20.8 2.04 0.61-6.85 .260 
 C25D1 36 22.2 8 37.5 0.41 0.06-2.59 .352 
Social functioning 
 C5D1 200 36.5 146 33.6 1.13 0.72-1.77 .599 
 C9D1 158 38.0 86 32.6 1.29 0.73-2.27 .386 
 C19D1 67 25.4 24 20.8 1.29 0.41-4.10 .649 
 C25D1 36 33.3 8 12.5 1.61 0.15-16.79 .695 
Nausea and vomiting 
 C5D1 200 14.5 146 12.3 1.20 0.64-2.25 .560 
 C9D1 158 10.8 86 16.3 0.61 0.28-1.33 .223 
 C19D1 67 10.4 24 4.2 4.50 0.28-72.12 .301 
 C25D1 36 2.8 8 12.5 0.20 0.01-4.17 .276 
Dyspnea 
 C5D1 200 28.0 146 24.0 1.18 0.72-1.93 .520 
 C9D1 158 25.3 86 29.1 0.75 0.41-1.37 .352 
 C19D1 67 10.4 24 20.8 0.48 0.12-1.94 .331 
 C25D1 36 16.7 8 50.0 0.27 0.04-1.89 .198 
Insomnia 
 C5D1 200 23.0 146 25.3 0.85 0.51-1.41 .529 
 C9D1 158 20.9 86 25.6 0.75 0.40-1.40 .360 
 C19D1 67 14.9 24 8.3 1.87 0.38-9.29 .445 
 C25D1 36 5.6 8 25.0 0.13 0.01-1.28 .067 
Appetite loss 
 C5D1 200 20.5 146 16.4 1.42 0.81-2.48 .213 
 C9D1 158 22.2 86 20.9 1.09 0.58-2.05 .792 
 C19D1 67 17.9 24 8.3 1.87 0.38-9.25 .446 






OR 95% CI P value n % Worsening 
n % 
Worsening 
 C5D1 200 32.5 146 28.8 1.13 0.71-1.81 .611 
 C9D1 158 30.4 86 18.6 1.85 0.96-3.55 .066 
 C19D1 67 26.9 24 12.5 2.44 0.59-10.16 .220 
 C25D1 36 13.9 8 0.0 NE NE-NE .304 
Diarrhea 
 C5D1 200 17.5 146 11.0 1.73 0.91-3.30 .095 
 C9D1 158 22.2 86 20.9 1.04 0.54-2.00 .896 
 C19D1 67 16.4 24 12.5 1.35 0.35-5.13 .648 
 C25D1 36 8.3 8 12.5 0.44 0.03-5.71 .534 
Financial difficulties 
 C5D1 200 15.5 146 11.6 1.30 0.68-2.48 .428 
 C9D1 158 12.7 86 14.0 0.96 0.44-2.07 .916 
 C19D1 67 7.5 24 16.7 0.26 0.05-1.26 .050 
 C25D1 36 8.3 8 12.5 0.20 0.01-4.17 .276 
Future perspective 
 C5D1 199 23.1 144 20.1 1.17 0.69-1.98 .563 
 C9D1 158 22.8 84 20.2 1.21 0.61-2.40 .589 
 C19D1 67 20.9 23 17.4 1.27 0.38-4.27 .699 
 C25D1 35 20.0 8 12.5 0.60 0.05-7.00 .675 
Body image 
 C5D1 199 27.1 144 20.1 1.44 0.87-2.39 .149 
 C9D1 158 22.2 83 20.5 1.08 0.56-2.07 .825 
 C19D1 67 20.9 23 39.1 0.31 0.11-0.91 .031 
 C25D1 35 22.9 8 25.0 1.33 0.14-12.5 .802 
C, cycle; D, day; NE, not evaluable; OR, odds ratio; PVd, pomalidomide in combination with bortezomib 
and low-dose dexamethasone; Vd, bortezomib and low-dose dexamethasone. 
A ≥ 10-point worsening from baseline was considered clinically meaningful. ORs were estimated using 
the Cochran-Mantel-Haenszel test with modified ridit scores stratified by randomization stratification 
factors. 
a A common OR at the C5D1 visit was reported, but the Breslow-Day test shows significant heterogeneity 





Adherence rates for European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 over time. A. Eligible patients 
at each cycle. B. Intent-to-treat population. 
BTZ+LD-DEX, bortezomib and low-dose dexamethasone; EOT, end of treatment; POM+BTZ+LD-DEX, pomalidomide in 
combination with bortezomib and low-dose dexamethasone. 








Cumulative distribution function curves for the global quality-of-life (QoL) domain of the QLQ-C30. 








Differences in overall least-squares (LS) mean changes from baseline between pomalidomide in combination with bortezomib and 
low-dose dexamethasone and bortezomib and low-dose dexamethasone. A. Functional domains. B. Symptom domains.  
Within-group LS mean changes and differences between groups were estimated based on a random intercept/slope model under the 
assumption of unstructured covariance and with the following covariates as fixed effects: baseline domain score, age, number of prior 
anti-myeloma regimens, β2-microglobulin, treatment, visit, treatment-by-visit interaction, and baseline domain score-by-visit 
interaction.  
 
 
 
 
